Ipsen Shares Decline Over 2% and Break Below Short-Term Moving Averages
In mid-morning trading in Paris, the biopharmaceutical company continues its decline in a downward-trending Parisian market. The stock is erasing some of the gains made in recent weeks and appears technically weakened, while the consensus among analysts remains generally neutral on the stock.
The Stock Falls Below Its Short-Term Moving Averages and Nears Its Support at €154.40
Ipsen shares are down 2.18% at €157.10, bringing its weekly decline to 5.36%. The stock has fallen below its MM20 (€163.72, a -4.04% deviation) and MM50 (€160.94, a -2.39% deviation), after hitting resistance at €170.80 at the end of June. The RSI at 46 remains neutral, with no sign of overselling.
However, the stock still maintains a comfortable cushion above its MM200 at €143.92, with a +9.16% deviation, indicating the strength of the medium-term trend and a nearly 50% increase over the year. The next support level to watch on the downside is at €154.40.
A Decline Following Clinical Announcements and Recent External Growth Operations
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Today's decline is part of a consolidation phase that began after the Phase III results for Dysport were announced on July 9, for the prevention of migraines. The company had expanded its operations in June and early July, with the acquisitions of Kartos Therapeutics for $450 million in oncology and Memo Therapeutics for up to €700 million in rare diseases. Regarding analyst opinions, CIC Market Solutions reaffirmed its buy rating on July 15, with a target price maintained at €175.00, representing a potential of about 11% from the current price. When the 2026 accounts were published at the end of May, the company highlighted the clinical results of IQIRVO, with an improvement observed in 67% of treated patients.
SectorSanté · Vaccins et laboratoires de recherche›Industrie Pharmaceutique
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1074.9M€
Guidance from the release
Ipsen a réalisé un excellent début d'année 2026.
Croissance soutenue grâce aux trois aires thérapeutiques.
Risks mentioned
pression réglementaire anticipée sur de nouveaux médicaments
concurrence accrue sur Somatuline à cause des génériques
Opportunities identified
croissance des ventes totales du Groupe supérieure à 13,0 %
lancement de trois nouveaux programmes en phase avancée
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
